Shares of drug delivery systems manufacturer Unilife Corp (NASDAQ:UNIS) recently rallied after it announced a long-term contract to sell prefilled syringes to pharma giant Sanofi SA (ADR) (NYSE:SNY). The deal allows Sanofi to sell its blood thinner Lovenox in Unilife’s Unifill Finesse prefilled syringes.
Sanofi SA (ADR) (NYSE:SNY) will pay an upfront payment of $5 million, which Unilife Corp (NASDAQ:UNIS) expects to receive within the next two months. From this deal, Unilife expects $5 million to $15 million in sales milestone payments, as well as royalties on future syringe sales.
In the first four years of the deal, Sanofi will purchase an undisclosed “high volume” minimum amount of syringes from Unilife Corp (NASDAQ:UNIS). After those four years, which Unilife refers to as a “ramp-up” period, Sanofi SA (ADR) (NYSE:SNY) will be required to purchase 150 million more syringes annually to retain marketing exclusivity.
A road paved with lofty promises
Using a $0.70 per syringe price as a cost basis, Jefferies & Co. analyst Raj Denhoy estimated that the deal would generate $105 million in additional revenue for Unilife Corp (NASDAQ:UNIS) after the first four years — a huge jump for a company that only generated $2.7 million in fiscal 2013 revenue.
The deal with Sanofi SA (ADR) (NYSE:SNY) could ideally increase the size of the company exponentially once those four years are over. However, Unilife’s unwillingness to disclose Sanofi’s orders for the first four years of its new deal keeps investors in the dark regarding its revenue growth rate.
This is the second time Sanofi SA (ADR) (NYSE:SNY) has helped Unilife Corp (NASDAQ:UNIS) — the first time being a $40 million multi-year deal signed in 2008 for the exclusive right to purchase Unifill, which expires in June 2014.
Unilife had also attracted bullish interest in June, when the company signed a 15-year contract with Biodel Inc (NASDAQ:BIOD) to administer its novel glucagon rescue drug for severe hypoglycemia through its EZMix platform. Although Unilife expects the agreement to eventually generate $110 million in annual sales, the drug is still a long way from approval with Biodel possibly filing an new drug application, or NDA, in 2015.
Unilife’s deals with Sanofi and Biodel Inc (NASDAQ:BIOD) reveal the wobbly weakness of the company’s strategy of signing long-term deals now to let investors estimate the company’s future value.
How does Unilife’s fundamentals stack up?
Considering that these two deals are the only two collaborations supporting Unilife’s stock right now, we need to analyze a snapshot of the company’s financial situation.
It’s not hard to see why Unilife is still unprofitable — its measly $2.7 million in 2013 revenue was burned straight through by its high long-term debt, rising expenses, negative cash flow, and dwindling cash reserves.
A look at Unilife’s fundamentals against a key industry peer, Antares Pharma Inc (NASDAQ:ATRS), doesn’t inspire much confidence. Antares specializes in self-injection pharmaceutical products and topical gel-based products. Unilife, by comparison, has a broader portfolio of prefilled syringes with automatic needle retraction, auto-injectors, wearable injectors, drug constitution delivery systems, and targeted delivery systems.
|Forward P/E||Price to Sales||Return on Equity||Debt to Equity||Qty. Revenue Growth (y-o-y)||Operating Margin|
|Antares Pharma||N/A||25.72||(29.98%)||No debt||29.00%||(79.33%)|
With past negative sales growth, deeply negative margins, a higher debt load, and an unstable P/S ratio, there aren’t any convincing fundamental reasons to own Unilife. Unilife’s net losses of $63.2 million in fiscal 2013 represent a 20% dip deeper into unprofitability.
Could Antares become a disruptive threat?
More importantly, Antares is a disruptive threat to Unilife because it specializes in needle-free injectors that use high pressure to push medicine through tiny openings in the skin. If these needleless injectors ever catch on, traditional syringes — which Unilife produces a lot of — could become obsolete. Unilife CEO Alan Shortall brushes aside those concerns, however, claiming that his company’s wearable injectors will eventually become a “billion dollar franchise.”